{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:28:01Z","timestamp":1783744081567,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.12.021","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T15:26:52Z","timestamp":1671118012000},"page":"795-804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP\u223cT vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-441X","authenticated-orcid":false,"given":"K.","family":"Maertens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.P.","family":"Orije","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Huoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Boisnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Lyabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.12.021_b0005","doi-asserted-by":"crossref","unstructured":"Decker M, Edwards K, Bogaerts H. Combination vaccines. In: Plotkin SA Orenstein WA, Offit PA, Edwards KM, editors. Vaccines. 7th ed. PA, USA: Elsevier; 2018. p. 198-227.","DOI":"10.1016\/B978-0-323-35761-6.00015-8"},{"key":"10.1016\/j.vaccine.2022.12.021_b0010","doi-asserted-by":"crossref","unstructured":"Lyseng-Williamson KM, PL. DTaP-IPV-Hep B-Hib vaccine (Hexyon\u00ae\/Haxacima\u00ae): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe. Drugs & Therapy Perspectives. 2013;29(11):329-35.","DOI":"10.1007\/s40267-013-0078-0"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.021_b0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40272-013-0007-7","article-title":"DTaP-IPV-Hep B-Hib vaccine (Hexaxim\u00ae): a review of its use in primary and booster vaccination","volume":"15","author":"McCormack","year":"2013","journal-title":"Paediatr Drugs"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.021_b0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/14712598.2013.774368","article-title":"Review of a new fully liquid, hexavalent vaccine: Hexaxim","volume":"13","author":"Nunes","year":"2013","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2022.12.021_b0025","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40272-019-00353-7","article-title":"DTaP-IPV-HepB-Hib vaccine (Hexyon\u00ae): an updated review of its use in primary and booster vaccination","volume":"21","author":"Syed","year":"2019","journal-title":"Paediatr Drugs"},{"issue":"36","key":"10.1016\/j.vaccine.2022.12.021_b0030","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1016\/j.vaccine.2017.06.063","article-title":"New perspectives for hexavalent vaccines","volume":"36","author":"Obando-Pacheco","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.021_b0035","doi-asserted-by":"crossref","unstructured":"Edwards K, Decker M. Pertussis vaccines. In: Plotkin SA Orenstein WA, Offit PA, Edwards KM, editors. Vaccines. 7th ed. PA, USA: Elsevier; 2018. p. 711-61.","DOI":"10.1016\/B978-0-323-35761-6.00043-2"},{"key":"10.1016\/j.vaccine.2022.12.021_b0040","doi-asserted-by":"crossref","unstructured":"Edwards KM. Unraveling the challenges of pertussis. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(2):575-6.","DOI":"10.1073\/pnas.1321360111"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.021_b0045","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/QCO.0b013e3283607a58","article-title":"Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants","volume":"26","author":"Lindsey","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.021_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g4219","article-title":"Safety of pertussis vaccination in pregnant women in UK: observational study","volume":"349","author":"Donegan","year":"2014","journal-title":"BMJ"},{"issue":"42","key":"10.1016\/j.vaccine.2022.12.021_b0055","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1016\/j.vaccine.2018.07.012","article-title":"Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women","volume":"36","author":"Fortner","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.12.021_b0060","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/AOG.0000000000000862","article-title":"Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination","volume":"125","author":"Morgan","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"17","key":"10.1016\/j.vaccine.2022.12.021_b0065","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1001\/jama.2014.3633","article-title":"Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial","volume":"311","author":"Munoz","year":"2014","journal-title":"J Am Med Assoc"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.021_b0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.vaccine.2015.10.100","article-title":"Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study","volume":"34","author":"Maertens","year":"2016","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2022.12.021_b0075","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1016\/j.vaccine.2016.04.066","article-title":"Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age","volume":"34","author":"Maertens","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.021_b0080","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1473-3099(18)30717-5","article-title":"Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial","volume":"19","author":"Barug","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.12.021_b0085","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/cid\/ciy244","article-title":"A randomized controlled trial of the safety and immunogenicity of tetanus, diphtheria, and acellular pertussis vaccine immunization during pregnancy and subsequent infant immune response","volume":"67","author":"Halperin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2022.12.021_b0090","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/INF.0b013e3182a09b6a","article-title":"Immune responses in infants whose mothers received Tdap vaccine during pregnancy","volume":"32","author":"Hardy-Fairbanks","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.vaccine.2022.12.021_b0095","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/civ695","article-title":"Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator","volume":"61","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.021_b0100","doi-asserted-by":"crossref","first-page":"e20153854","DOI":"10.1542\/peds.2015-3854","article-title":"Pertussis antibody concentrations in infants born prematurely to mothers vaccinated in pregnancy","volume":"138","author":"Kent","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2022.12.021_b0105","article-title":"Pertussis immunization during pregnancy: assessment of the role of maternal antibodies on immune responses in term and preterm born infants","author":"Maertens","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"37","key":"10.1016\/j.vaccine.2022.12.021_b0110","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1016\/j.vaccine.2018.07.048","article-title":"Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines","volume":"36","author":"Itell","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.021_b0115","doi-asserted-by":"crossref","unstructured":"Varghese K, Bartlett W, Zheng L, Bookhout S, Vincent D, Huleatt J, et al. A new electrochemiluminescence-based multiplex assay for the assessment of human antibody responses to Bordetella pertussis vaccines. Infectious Diseases and Therapy. 2021;10(4).2359-2561.","DOI":"10.1007\/s40121-021-00530-7"},{"issue":"4","key":"10.1016\/j.vaccine.2022.12.021_b0120","doi-asserted-by":"crossref","first-page":"e249","DOI":"10.1016\/j.ijid.2010.12.004","volume":"15","author":"Kosalaraksa","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.021_b0125","doi-asserted-by":"crossref","unstructured":"Vesikari TS, SA; Jordanov, E; Feroldi E. A randomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3, 5 and 11-12 month schedule. The Pediatric Infectious Disease Journal. 2017;36(1):87-93.","DOI":"10.1097\/INF.0000000000001358"},{"issue":"11","key":"10.1016\/j.vaccine.2022.12.021_b0130","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1097\/INF.0000000000001682","article-title":"A randomized, controlled study of a fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccinations of healthy infants and toddlers in Latin America","volume":"36","author":"L\u00f3pez","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"10.1016\/j.vaccine.2022.12.021_b0135","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/INF.0b013e318292f7b1","article-title":"Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles\/mumps\/rubella and varicella vaccines at 15\u201318 months of age in healthy South African infants","volume":"32","author":"Madhi","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.vaccine.2022.12.021_b0140","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.vaccine.2016.11.053","article-title":"Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants","volume":"35","author":"Vesikari","year":"2017","journal-title":"Vaccine"},{"issue":"52","key":"10.1016\/j.vaccine.2022.12.021_b0145","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1016\/j.vaccine.2018.10.100","article-title":"Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers","volume":"36","author":"Vesikari","year":"2018","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.12.021_b0150","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.vaccine.2018.01.005","article-title":"Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity","volume":"36","author":"Omenaca","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.12.021_b0155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.vaccine.2015.10.098","article-title":"Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy","volume":"34","author":"Hoang","year":"2016","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2022.12.021_b0160","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1016\/j.vaccine.2018.03.033","article-title":"Coverage of recommended vaccines during pregnancy in Flanders, Belgium. Fairly good but can we do better?","volume":"36","author":"Maertens","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.12.021_b0165","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jpeds.2009.08.049","article-title":"Accounting for multiple births in neonatal and perinatal trials: systematic review and case study","volume":"156","author":"Hibbs","year":"2010","journal-title":"J Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:21:25Z","timestamp":1759404085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22015353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22015353"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of a liquid hexavalent DTaP-IPV-HB-PRP\u223cT vaccine after primary and booster vaccination of term and preterm infants born to women vaccinated with Tdap during pregnancy","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}